Polycystic kidney disease

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline – CNTA

Retrieved on: 
Monday, November 7, 2022
GLOBE, Complaint, Pomerantz, Company, Polycystic kidney disease, A1AT, AE, LLP, Prospectus, Person, Defendant, Securities Act of 1933, Class, DNA, SEC, Form, NASDAQ, News, U.S. Securities and Exchange Commission, Ext, Securities Exchange Act of 1934, AATD, BID, IPO, Observation, Autosome, Court, Liver, District court, ADS, Patient, American depositary receipt, Register, Registration statement, CNTA, Security (finance), Pharmaceutical industry, Animal

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, November 7, 2022
DNA, AATD, Fraud, DoorDash, U.S. Securities and Exchange Commission, Churn, Partnership, Acquisition, Form, Technology, SEC, Class, Bloomberg, Company, Prospectus, Growth, GLOBE, NYSE, IPO, SCH, Autosome, Tripura Merger Agreement, Initial, BID, Registration statement, Nasdaq, Polycystic kidney disease, Patient, PayPal, A1AT, Contract, Complaint, Farm, CNTA, Review, Defendant, ADS, Observation, AE, P.C, Class Action, Restaurant, Industry, PYPL, NNA, Register, NASDAQ, Risk, Liver, News, Holding company, Food delivery, Risk management, Audit, Medical device, Security (finance), Animal, Renewable energy, Cryptocurrency, Online shopping, Mergers and acquisitions, Subway, Opendoor, Algorithm

Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.

Key Points: 
  • Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.
  • By the first quarter of 2022, the Companys active locations had grown to approximately 82,000 a 19% increase over the prior year.
  • For more information on the Opendoor class action go to: https://bespc.com/cases/OPEN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

XORTX Presents New Proof of Concept Data at American Society of Nephrology

Retrieved on: 
Thursday, November 3, 2022
Xanthine oxidase, Kidney, International, Society, Uric acid, Coronavirus, Mouse, University, OXO, Cyst, Analysis, Form, SEC, Nephrology, Diabetes, Hyperuricemia, Growth, GLOBE, Incidence, Fibrosis, Autosome, CEO, Health, DS, Xanthine, Allantoin, Diagnosis, Polycystic kidney disease, Patient, TSX Venture Exchange, Research, Unitary state, University of Colorado Denver School of Public Affairs, Letter, Human, Quality of life, COVID-19, HIV disease progression rates, Life, No, Kidney disease, Urate oxidase, Conference, Abstract, Therapy, Nasdaq, Session, ASN, American Society of Nephrology, Chronic pain, NASDAQ, News, Association, Pharmaceutical industry, Sulfur, Gum arabic, ADPKD, Kidney stone disease, PKD, Creatinine

CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the presentation of a peer-reviewed abstract to be presented November 4, 2022 at the American Society of Nephrology (“ASN”) Annual Conference – Kidney Week.  The abstract presents new discoveries in two species – mouse and rat models of polycystic kidney disease (“PKD”) and reports original work showing the harmful consequence of chronically increased uric acid on both structure and function of kidneys. The Abstract “Raising Serum Uric Acid with a Uricase Inhibitor Worsens PKD in Rat and Mouse models” will be presented during the Session Title: Genetic Diseases of the Kidneys, by Dr. Charles Edelstein of the University of Colorado and Dr. Allen Davidoff, CEO of XORTX.  This presentation will report for the first time, that XORTX's XRx-008 formulation of Xanthine Oxidase inhibitor can substantially and significantly block the increase in kidney size associated with high circulating uric acid in a rodent model of polycystic kidney disease.

Key Points: 
  • The abstract presents the findings of studies conducted at the University of Colorado, by Dr. Charles Edelstein and the PKD research team.
  • Dr. Allen Davidoff, CEO of XORTX, stated, We are pleased to present these important new findings during the ASN Kidney Week 2022.
  • With these results presented today, XORTX now has the information required to prepare and pursue Orphan Drug Designation for XRx-008.
  • At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients.

Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Retrieved on: 
Tuesday, November 1, 2022
RNA transfection, RNA, Plasma, RMAS, Science, CF, Mutation, SEC, Clinical trial, Cancer, GLOBE, Patient, Royal commission, Research, Eukaryotic ribosome, COVID-19, Allele, Disease, COL4A3, File, European Commission, Degenerative disease, Cystic fibrosis, Proteinuria, Kidney disease, Safety, Genetic disorder, Patent, Judgement, COL4A5, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Private Securities Litigation Reform Act, Polycystic kidney disease, Hearing loss, FDA, Kidney, Food, Fast Track, Alport syndrome, Autosome, Forward-looking statement, Gene, COL4A4, Orphan, Pharmaceutical industry, Alport

Additional sites are expected to be opened and actively recruiting Alport patients in the coming weeks, said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.

Key Points: 
  • Additional sites are expected to be opened and actively recruiting Alport patients in the coming weeks, said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
  • Alport patients with nonsense mutations have significantly worse clinical outcomes than other Alport patients and have no disease modifying treatment options.
  • This proof-of-concept clinical trial will include up to eight Alport syndrome patients with nonsense mutations in the second half of 2022.
  • Approximately 6% to 7% of Alport syndrome patients, or approximately 9,400 to 12,750 individuals, are estimated to have nonsense mutations.

CENTESSA PHARMACEUTICALS PLC (NASDAQ: CNTA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Centessa Pharmaceuticals plc (NASDAQ: CNTA)

Retrieved on: 
Tuesday, November 1, 2022
Company, Securities Exchange Act of 1934, Central District, DNA, American depositary receipt, BID, District court, IPO, Liver, News, SEC, GLOBE, AE, Prospectus, AATD, Securities Act of 1933, Register, The Legal 500, Labour government, Court, ADS, Form, NEW, CNTA, NASDAQ, Investment, Observation, Polycystic kidney disease, Patient, American, A1AT, Advertising, Autosome, Defendant, Registration statement, Pharmaceutical industry, Security (finance)

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired: (a) Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ: CNTA) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about May 28, 2021 (the “IPO” or “Offering”); and/or (b) Centessa securities between May 28, 2021 and June 1, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Centessa Pharmaceuticals plc Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Centessa is a clinical-stage pharmaceutical company that purports to discover, develop, and deliver medicines to patients.
  • Plaintiff alleges that Defendants made materially false and misleading statements in the Offering Documents and throughout the Class Period.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, November 1, 2022
Warner, Growth, Churn, DNA, BID, Liver, SEC, GLOBE, HBO Max, PYPL, ADS, Investment, Warner Bros., Polycystic kidney disease, Company, AT, Complaint, Prospectus, IPO, Partnership, AE, NYSE, OLO, CNTA, NASDAQ, Restaurant, Observation, DoorDash, U.S. Securities and Exchange Commission, Patient, HBO, Securities Act of 1933, Section 11 of the Canadian Charter of Rights and Freedoms, Defendant, Registration statement, Acquisition, PayPal, Mergers and acquisitions, Farm, News, AATD, Register, Contract, NNA, Fraud, Form, A1AT, AT&T, Autosome, Class, Class Action, Music, Audit, Food delivery, Risk management, Security (finance), Animal, Online shopping, P.C, WarnerMedia, Discovery, Subway

Discovery, Inc. (NASDAQ: WBD), Olo, Inc. (NYSE: OLO), Centessa Pharmaceuticals Plc (NASDAQ: CNTA), and PayPal Holdings, Inc. (NASDAQ: PYPL).

Key Points: 
  • Discovery, Inc. (NASDAQ: WBD), Olo, Inc. (NYSE: OLO), Centessa Pharmaceuticals Plc (NASDAQ: CNTA), and PayPal Holdings, Inc. (NASDAQ: PYPL).
  • For more information on the Warner Bros. class action go to: https://bespc.com/cases/WBD
    Olo provides software to restaurants to assist with online ordering and food-delivery coordination.
  • For more information on the PayPal class action go to: https://bespc.com/cases/PYPL
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline – CNTA

Retrieved on: 
Sunday, October 30, 2022
NASDAQ, Polycystic kidney disease, Court, BID, Registration statement, District court, Form, Observation, LLP, Class, Person, Autosome, Securities Exchange Act of 1934, Securities Act of 1933, American depositary receipt, Defendant, AATD, Company, AE, Complaint, Register, Prospectus, GLOBE, U.S. Securities and Exchange Commission, CNTA, IPO, SEC, ADS, Pomerantz, Patient, News, A1AT, DNA, Ext, Liver, Security (finance), Pharmaceutical industry, Animal

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, October 27, 2022
U.S. Securities and Exchange Commission, NASDAQ, Churn, Polycystic kidney disease, CNTA, Lists of schools in England, AT, Securities Act of 1933, HBO Max, Registration statement, Class Action, Warner Bros., Liver, Observation, ADS, IPO, Patient, AT&T, Restaurant, News, DoorDash, Investment, Autosome, Farm, Â, A1AT, Partnership, Company, Form, Acquisition, AE, DNA, Growth, PayPal, Mergers and acquisitions, Section 11 of the Canadian Charter of Rights and Freedoms, Defendant, OLO, Prospectus, GLOBE, PYPL, NNA, HBO, SEC, Class, Contract, Register, Complaint, BID, AATD, Fraud, Warner, NYSE, Music, Audit, Food delivery, Risk management, Security (finance), Animal, Online shopping, P.C, Subway, Discovery, WarnerMedia

Discovery, Inc. (NASDAQ: WBD), Olo, Inc. (NYSE: OLO), Centessa Pharmaceuticals Plc (NASDAQ: CNTA), and PayPal Holdings, Inc. (NASDAQ: PYPL).

Key Points: 
  • Discovery, Inc. (NASDAQ: WBD), Olo, Inc. (NYSE: OLO), Centessa Pharmaceuticals Plc (NASDAQ: CNTA), and PayPal Holdings, Inc. (NASDAQ: PYPL).
  • For more information on the Warner Bros. class action go to: https://bespc.com/cases/WBD
    Olo provides software to restaurants to assist with online ordering and food-delivery coordination.
  • For more information on the PayPal class action go to: https://bespc.com/cases/PYPL
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

XORTX Receives Further No Objection Letter from Health Canada

Retrieved on: 
Wednesday, October 26, 2022
Knowledge, Diabetic nephropathy, Pharmacokinetics, Food, SEC, Form, Security (finance), U.S. Securities and Exchange Commission, Fibrosis, NASDAQ, Safety, Diagnosis, Analysis, Unitary state, Chronic pain, TSX Venture Exchange, Cyst, Polycystic kidney disease, CEO, Coronavirus, XRX, Kidney disease, Patient, NOL, New Drug Application, European Medicines Agency, International, Quality of life, Drug discovery, News, Uric acid, GLOBE, COVID-19, Tablet, Therapy, NDA, FDA, Xanthine oxidase, Autosome, Health Canada, Oxipurinol, Part, Incidence, No, Health, Pharmaceutical industry, Study, Nasdaq, ADPKD

The Study was originally designed as a three part study and a NOL was received by Health Canada in April (see April 12, 2022 press release).

Key Points: 
  • The Study was originally designed as a three part study and a NOL was received by Health Canada in April (see April 12, 2022 press release).
  • XORTX has successfully completed parts 1 and 2 of the Study, has modified part 3 and has added an additional part 4 as outlined below.
  • Dr. Allen Davidoff, CEO of XORTX stated, We are pleased to receive the NOL from Health Canada for the amended pharmacokinetic Study.
  • At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients.

XORTX Sponsored American Society of Nephrology Study Abstract Available Online

Retrieved on: 
Tuesday, October 25, 2022
Chronic endothelial injury hypothesis, Growth, TSX Venture Exchange, Incidence, Kidney, Research, Society, News, Mouse, NASDAQ, Nephrology, GLOBE, Life, Coronavirus, American Society of Nephrology, DS, Therapy, Patient, Quality of life, Kidney disease, CEO, Analysis, Conference, SEC, Session, International, University, Health, Polycystic kidney disease, Diagnosis, PCK, Abstract, HIV disease progression rates, Human, Oxidase test, ASN, Fibrosis, COVID-19, Form, Nasdaq, PKD, Diabetic nephropathy, University of Colorado Denver School of Public Affairs, Allantoin, Association, No, Chronic pain, Unitary state, Hyperuricemia, Autosome, Uric acid, Cyst, Letter, OXO, Urate oxidase, Xanthine oxidase, Pharmaceutical industry, Gum arabic, ADPKD, Creatinine, Kidney stone disease

CALGARY, Alberta, Oct. 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce online availability of the peer-reviewed abstract to be presented November 4, 2022 at the American Society of Nephrology (“ASN”) Annual Conference – Kidney Week. The abstract presents new discoveries in two species – mouse and rat models of polycystic kidney disease (“PKD”) and reports original work showing the harmful consequence of chronically increased uric acid on both structure and function of kidneys. The Abstract “Raising Serum Uric Acid with a Uricase Inhibitor Worsens PKD in Rat and Mouse models” will be presented during the Session Title: Genetic Diseases of the Kidneys, by Dr. Charles Edelstein of the University of Colorado and Dr. Allen Davidoff of XORTX. 

Key Points: 
  • The abstract presents the findings of studies conducted at the University of Colorado, by Dr. Charles Edelstein and the PKD research team.
  • The aim of this study was to determine whether raising serum uric acid with OXO was associated with worse PKD.
  • We anticipate a further updated information near the time that the abstract for the ASN becomes public.
  • At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients.